Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. T...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Loc, Nguyen Vo Vinh [verfasserIn] Vuong, Nguyen Lam Trung, Lam Viet Trung, Tran Thien

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	Esophageal cancer Time to surgery Neoadjuvant chemotherapy Esophagectomy

Anmerkung:	© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Übergeordnetes Werk:	Enthalten in: International journal of gastrointestinal cancer - Totowa, NJ : Humana Press, 1986, 54(2023), 4 vom: 01. Feb., Seite 1240-1251
Übergeordnetes Werk:	volume:54 ; year:2023 ; number:4 ; day:01 ; month:02 ; pages:1240-1251

Links:	Volltext

DOI / URN:	10.1007/s12029-023-00915-6

Katalog-ID:	SPR054199735

Internformat


LEADER	01000naa a22002652 4500
001	SPR054199735
003	DE-627
005	20231229064639.0
007	cr uuu---uuuuu
008	231229s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s12029-023-00915-6 \|2 doi
035			\|a (DE-627)SPR054199735
035			\|a (SPR)s12029-023-00915-6-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Loc, Nguyen Vo Vinh \|e verfasserin \|4 aut
245	1	0	\|a Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
520			\|a Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials.
650		4	\|a Esophageal cancer \|7 (dpeaa)DE-He213
650		4	\|a Time to surgery \|7 (dpeaa)DE-He213
650		4	\|a Neoadjuvant chemotherapy \|7 (dpeaa)DE-He213
650		4	\|a Esophagectomy \|7 (dpeaa)DE-He213
700	1		\|a Vuong, Nguyen Lam \|4 aut
700	1		\|a Trung, Lam Viet \|4 aut
700	1		\|a Trung, Tran Thien \|4 aut
773	0	8	\|i Enthalten in \|t International journal of gastrointestinal cancer \|d Totowa, NJ : Humana Press, 1986 \|g 54(2023), 4 vom: 01. Feb., Seite 1240-1251 \|w (DE-627)363738215 \|w (DE-600)2103370-5 \|x 1559-0739 \|7 nnns
773	1	8	\|g volume:54 \|g year:2023 \|g number:4 \|g day:01 \|g month:02 \|g pages:1240-1251
856	4	0	\|u https://dx.doi.org/10.1007/s12029-023-00915-6 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
951			\|a AR
952			\|d 54 \|j 2023 \|e 4 \|b 01 \|c 02 \|h 1240-1251

Indexfelder

author_variant	n v v l nvv nvvl n l v nl nlv l v t lv lvt t t t tt ttt
matchkey_str	article:15590739:2023----::fetfieoiialivsveohgcoyfenoduathmteayoeo
hierarchy_sort_str	2023
publishDate	2023
allfields	10.1007/s12029-023-00915-6 doi (DE-627)SPR054199735 (SPR)s12029-023-00915-6-e DE-627 ger DE-627 rakwb eng Loc, Nguyen Vo Vinh verfasserin aut Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials. Esophageal cancer (dpeaa)DE-He213 Time to surgery (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Esophagectomy (dpeaa)DE-He213 Vuong, Nguyen Lam aut Trung, Lam Viet aut Trung, Tran Thien aut Enthalten in International journal of gastrointestinal cancer Totowa, NJ : Humana Press, 1986 54(2023), 4 vom: 01. Feb., Seite 1240-1251 (DE-627)363738215 (DE-600)2103370-5 1559-0739 nnns volume:54 year:2023 number:4 day:01 month:02 pages:1240-1251 https://dx.doi.org/10.1007/s12029-023-00915-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 54 2023 4 01 02 1240-1251
spelling	10.1007/s12029-023-00915-6 doi (DE-627)SPR054199735 (SPR)s12029-023-00915-6-e DE-627 ger DE-627 rakwb eng Loc, Nguyen Vo Vinh verfasserin aut Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials. Esophageal cancer (dpeaa)DE-He213 Time to surgery (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Esophagectomy (dpeaa)DE-He213 Vuong, Nguyen Lam aut Trung, Lam Viet aut Trung, Tran Thien aut Enthalten in International journal of gastrointestinal cancer Totowa, NJ : Humana Press, 1986 54(2023), 4 vom: 01. Feb., Seite 1240-1251 (DE-627)363738215 (DE-600)2103370-5 1559-0739 nnns volume:54 year:2023 number:4 day:01 month:02 pages:1240-1251 https://dx.doi.org/10.1007/s12029-023-00915-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 54 2023 4 01 02 1240-1251
allfields_unstemmed	10.1007/s12029-023-00915-6 doi (DE-627)SPR054199735 (SPR)s12029-023-00915-6-e DE-627 ger DE-627 rakwb eng Loc, Nguyen Vo Vinh verfasserin aut Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials. Esophageal cancer (dpeaa)DE-He213 Time to surgery (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Esophagectomy (dpeaa)DE-He213 Vuong, Nguyen Lam aut Trung, Lam Viet aut Trung, Tran Thien aut Enthalten in International journal of gastrointestinal cancer Totowa, NJ : Humana Press, 1986 54(2023), 4 vom: 01. Feb., Seite 1240-1251 (DE-627)363738215 (DE-600)2103370-5 1559-0739 nnns volume:54 year:2023 number:4 day:01 month:02 pages:1240-1251 https://dx.doi.org/10.1007/s12029-023-00915-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 54 2023 4 01 02 1240-1251
allfieldsGer	10.1007/s12029-023-00915-6 doi (DE-627)SPR054199735 (SPR)s12029-023-00915-6-e DE-627 ger DE-627 rakwb eng Loc, Nguyen Vo Vinh verfasserin aut Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials. Esophageal cancer (dpeaa)DE-He213 Time to surgery (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Esophagectomy (dpeaa)DE-He213 Vuong, Nguyen Lam aut Trung, Lam Viet aut Trung, Tran Thien aut Enthalten in International journal of gastrointestinal cancer Totowa, NJ : Humana Press, 1986 54(2023), 4 vom: 01. Feb., Seite 1240-1251 (DE-627)363738215 (DE-600)2103370-5 1559-0739 nnns volume:54 year:2023 number:4 day:01 month:02 pages:1240-1251 https://dx.doi.org/10.1007/s12029-023-00915-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 54 2023 4 01 02 1240-1251
allfieldsSound	10.1007/s12029-023-00915-6 doi (DE-627)SPR054199735 (SPR)s12029-023-00915-6-e DE-627 ger DE-627 rakwb eng Loc, Nguyen Vo Vinh verfasserin aut Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials. Esophageal cancer (dpeaa)DE-He213 Time to surgery (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Esophagectomy (dpeaa)DE-He213 Vuong, Nguyen Lam aut Trung, Lam Viet aut Trung, Tran Thien aut Enthalten in International journal of gastrointestinal cancer Totowa, NJ : Humana Press, 1986 54(2023), 4 vom: 01. Feb., Seite 1240-1251 (DE-627)363738215 (DE-600)2103370-5 1559-0739 nnns volume:54 year:2023 number:4 day:01 month:02 pages:1240-1251 https://dx.doi.org/10.1007/s12029-023-00915-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 54 2023 4 01 02 1240-1251
language	English
source	Enthalten in International journal of gastrointestinal cancer 54(2023), 4 vom: 01. Feb., Seite 1240-1251 volume:54 year:2023 number:4 day:01 month:02 pages:1240-1251
sourceStr	Enthalten in International journal of gastrointestinal cancer 54(2023), 4 vom: 01. Feb., Seite 1240-1251 volume:54 year:2023 number:4 day:01 month:02 pages:1240-1251
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Esophageal cancer Time to surgery Neoadjuvant chemotherapy Esophagectomy
isfreeaccess_bool	false
container_title	International journal of gastrointestinal cancer
authorswithroles_txt_mv	Loc, Nguyen Vo Vinh @@aut@@ Vuong, Nguyen Lam @@aut@@ Trung, Lam Viet @@aut@@ Trung, Tran Thien @@aut@@
publishDateDaySort_date	2023-02-01T00:00:00Z
hierarchy_top_id	363738215
id	SPR054199735
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR054199735</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20231229064639.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">231229s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12029-023-00915-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR054199735</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12029-023-00915-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Loc, Nguyen Vo Vinh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophageal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Time to surgery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophagectomy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vuong, Nguyen Lam</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trung, Lam Viet</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trung, Tran Thien</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">International journal of gastrointestinal cancer</subfield><subfield code="d">Totowa, NJ : Humana Press, 1986</subfield><subfield code="g">54(2023), 4 vom: 01. Feb., Seite 1240-1251</subfield><subfield code="w">(DE-627)363738215</subfield><subfield code="w">(DE-600)2103370-5</subfield><subfield code="x">1559-0739</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:54</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:4</subfield><subfield code="g">day:01</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:1240-1251</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12029-023-00915-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">54</subfield><subfield code="j">2023</subfield><subfield code="e">4</subfield><subfield code="b">01</subfield><subfield code="c">02</subfield><subfield code="h">1240-1251</subfield></datafield></record></collection>
author	Loc, Nguyen Vo Vinh
spellingShingle	Loc, Nguyen Vo Vinh misc Esophageal cancer misc Time to surgery misc Neoadjuvant chemotherapy misc Esophagectomy Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
authorStr	Loc, Nguyen Vo Vinh
ppnlink_with_tag_str_mv	@@773@@(DE-627)363738215
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1559-0739
topic_title	Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma Esophageal cancer (dpeaa)DE-He213 Time to surgery (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Esophagectomy (dpeaa)DE-He213
topic	misc Esophageal cancer misc Time to surgery misc Neoadjuvant chemotherapy misc Esophagectomy
topic_unstemmed	misc Esophageal cancer misc Time to surgery misc Neoadjuvant chemotherapy misc Esophagectomy
topic_browse	misc Esophageal cancer misc Time to surgery misc Neoadjuvant chemotherapy misc Esophagectomy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	International journal of gastrointestinal cancer
hierarchy_parent_id	363738215
hierarchy_top_title	International journal of gastrointestinal cancer
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)363738215 (DE-600)2103370-5
title	Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
ctrlnum	(DE-627)SPR054199735 (SPR)s12029-023-00915-6-e
title_full	Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
author_sort	Loc, Nguyen Vo Vinh
journal	International journal of gastrointestinal cancer
journalStr	International journal of gastrointestinal cancer
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
container_start_page	1240
author_browse	Loc, Nguyen Vo Vinh Vuong, Nguyen Lam Trung, Lam Viet Trung, Tran Thien
container_volume	54
format_se	Elektronische Aufsätze
author-letter	Loc, Nguyen Vo Vinh
doi_str_mv	10.1007/s12029-023-00915-6
title_sort	effect of time to minimally invasive esophagectomy after neoadjuvant chemotherapy for esophageal squamous cell carcinoma
title_auth	Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
abstract	Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
abstractGer	Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
abstract_unstemmed	Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702
container_issue	4
title_short	Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
url	https://dx.doi.org/10.1007/s12029-023-00915-6
remote_bool	true
author2	Vuong, Nguyen Lam Trung, Lam Viet Trung, Tran Thien
author2Str	Vuong, Nguyen Lam Trung, Lam Viet Trung, Tran Thien
ppnlink	363738215
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s12029-023-00915-6
up_date	2024-07-04T00:25:30.795Z
_version_	1803606012248195072
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR054199735</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20231229064639.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">231229s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12029-023-00915-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR054199735</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12029-023-00915-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Loc, Nguyen Vo Vinh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil/capecitabine (DCF/DCX) followed by esophagectomy has been the recommended treatment for esophageal squamous cell carcinoma (ESCC). However, the optimal interval from NAC to surgery has not yet been established. This study evaluated the impact of time to surgery (TTS) in the treatment of ESCC. Methods Between August 2018 and September 2021, 97 patients who underwent radical esophagectomy following 3–6 cycles of NAC with DCF/DCX for ESCC at a single hospital were analyzed. TTS was categorized into three groups: 16–41 days (group 1; 33 patients), 42–55 days (group 2; 29 patients), and 56–135 days (group 3; 35 patients). Survival outcomes included overall survival (OS) and progression-free survival (PFS). Results Mean age was 59.6 ± 6.8 years, and 95 patients were male. One patient had grade-III anemia, 12 had grade-II anemia, and four had grade-II neutropenia; all other NAC-related toxicities were as grade I. Regarding pathologic tumor response, 18.6% achieved complete response, 71.1% achieved partial response, and 10.3% had stable disease. Forty-eight patients (49.5%) had a postoperative complication, but only six (6.2%) with grade IIIa and two (2.1%) with grade IVa according to the Clavien-Dindo classification. Median follow-up time was 24 months. Groups 1 and 3 had worse OS (HR [95% CI]: 3.36 [1.16–11.7] and 1.83 [0.55–6.10]) and worse PFS (HR [95% CI]: 3.27 [1.25–8.53] and 1.61 [0.58–4.45]) compared to group 2. Conclusion We suggest the optimal TTS after NAC is 6–8 weeks. However, this finding must be confirmed by prospective trials.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophageal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Time to surgery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophagectomy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vuong, Nguyen Lam</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trung, Lam Viet</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trung, Tran Thien</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">International journal of gastrointestinal cancer</subfield><subfield code="d">Totowa, NJ : Humana Press, 1986</subfield><subfield code="g">54(2023), 4 vom: 01. Feb., Seite 1240-1251</subfield><subfield code="w">(DE-627)363738215</subfield><subfield code="w">(DE-600)2103370-5</subfield><subfield code="x">1559-0739</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:54</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:4</subfield><subfield code="g">day:01</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:1240-1251</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12029-023-00915-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">54</subfield><subfield code="j">2023</subfield><subfield code="e">4</subfield><subfield code="b">01</subfield><subfield code="c">02</subfield><subfield code="h">1240-1251</subfield></datafield></record></collection>
score	7.4018164

Nicht das Richtige dabei?

Schreiben Sie uns!

Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?